FDA Issues Additional Warning to Diabetics Taking Invokana Inokamet
The Food and Drug Administration (FDA) has recently strengthened its warning for diabetics taking Invokana, Invokamet (canagliflozin).
According to a June 14, 2016, FDA statement, from March 2013, when canagliflozin was approved, to October 2015, FDA received reports of 101 confirmable cases* of acute kidney injury, some requiring hospitalization and dialysis, with canagliflozin or dapagliflozin use.
This new warning adds to previous warnings from the FDA. In the past, the government agency stated canagliflozin, a sodium-glucose cotransporter-2 (SGLT2) drug, may cause an increased the risk of developing ketoacidosis. For patients taking Invokana this can result in the dangerous, at times, life-threatening condition, occurring as the body produces unnaturally high levels of blood acids. Ketoacidosis may then lead to hospitalizations, kidney damage, diabetic coma or even death.
Meyers & Flowers continues to fight for the rights of Invokana patients who have experienced ketoacidosis and their families, read more about how here.